Fda Clears Rapid Assay For *Aspergillus* Antigen {#sec1}
================================================

19 May (Reuters Health)---The US Food and Drug Administration (FDA) said that it cleared Bio-Rad Laboratories\' 3-hour blood test for aspergillus, a cause of invasive fungal infections that can be fatal in immunocompromised patients.

The product is the first rapid lab test for the infection, the agency said. Traditional testing methods take about 4 weeks, it noted.

The fungal infection most often occurs in leukemia patients, organ and bone marrow transplant patients, and patients whose immune systems are compromised by illness or chemotherapy. Although it affects only a few thousand people a year, according to federal figures, the mortality rates range between 50% and 100%

The FDA said clearance was based on a comparison of testing done at 3 cancer centers on 1890 blood samples from 170 people. The results showed that the new test\'s sensitivity was 80.7% and its specificity was 89.2%.

The FDA earlier cleared the Bio-Rad test for use in a trial funded by the National Institutes of Health aimed at finding potential new treatments for the infection.

Infection Control Best Defense Against Sars Super-Spreaders {#sec2}
===========================================================

19 May (Reuters Health \[Marilynn Larkin\])---" Super-spreaders" of severe acute respiratory syndrome (SARS) are unlikely to be infected with a particularly virulent form of the disease and are best dealt with by isolation and quarantine. That\'s the word from panelists at a conference, "SARS in the Context of Emerging Infectious Threats," held at the New York Academy of Sciences.

"We saw most clearly in Singapore that secondary cases are linked to other cases and that quarantine can limit transmission," asserted Dr. Larry Anderson of the US Centers for Disease Control and Prevention in Atlanta. "We had a few superspreaders--- 5 people, each of whom had infected more than 10 others. But it wasn\'t virus-specific---that is, those who were infected did not then become superspreaders."

In Toronto, the experience was similar, said Dr. Donald Low of Mt. Sinai, who treated the early cases there. "We had 1 'case B' patient who infected 9 others and 1 congestive heart failure patient who infected 21. But this was because SARS was not recognized early enough; the patients went home and infected family members or healthcare workers in the emergency department and \[coronary surgery\] ward."

In one instance, 6 health care workers became infected during an intubation, which is now considered a high-risk activity in SARS patients. Infection was probably due to droplet dispersion that occurred when the intubation became "difficult," he said.

Promising Targets For Sars Vaccines And Treatments Emerge {#sec3}
=========================================================

19 May (Reuters Health \[Marilynn Larkin\])--- In a spirited full-day symposium at the New York Academy of Sciences, scientists from industry and the US National Institutes of Allergy and Infectious Diseases (NIAID) agreed that "unprecedented, rapid progress" has been made in identifying potential vaccine strategies and drug treatments for severe acute respiratory syndrome (SARS).

"People are galvanized, particularly in China, where there is a massive effort underway to develop killed and sub-unit vaccines and viral vectors, and to test the use of convalescent serum against the disease," said symposium chair Dr. Scott Hammer, chief of the Division of Infectious Medicine at Columbia Presbyterian Medical Center in New York City.

Dr. David Ho, scientific director of the Aaron Diamond AIDS Research Center, also in New York City, reported that he took candidate fusion inhibitors--- peptides that could inhibit SARS virus entry and replication in cells---to Hong Kong 2 weeks ago, and that "preliminary results suggest that 5 of 12 had antiviral activity in varying concentrations." None were toxic and all appeared to be SARSspecific--- that is, peptides that blocked SARS fusion did not block HIV fusion.

Dr. C. Richter King of GenVec in Gaithersburg, Maryland, said his company is one of several that are using adenovirus vector technology to target the surface glycoprotein of SARS. "We\'ve used similar technology for HIV, malaria, and dengue virus," he noted. "It\'s versatile, well tolerated, and---importantly---manufacturable on a large scale."

Dr. Thomas Monath of Acambis in Cambridge, Massachusetts, said his company is collaborating closely with veterinarians who have worked with coronavirus vaccines to treat animals, even though it is unclear whether the coronavirus that causes SARS jumped the species barrier or evolved separately.

Representatives of Merck, Bristol- Myers Squibb, and Pfizer, who participated in a short panel discussion, acknowledged that work is underway on vaccines and treatments, but offered no specifics. All cautioned that, at best, a commercially available vaccine might be expected in 5 or 6 years.

***Editor\'s comment***. Although a vaccine for SARS is probably years away, it is of interest to keep informed of the many efforts in progress to develop one.

Smallpox Immunity Lasts Decades, Study Shows {#sec4}
============================================

20 May (Reuters Health \[Maggie Fox\])--- Immunity to smallpox lasts virtually a lifetime, researchers said in a report that suggests anyone vaccinated in the past still has some protection if the virus is used in a bioterrorism attack.

Tests of people who were vaccinated as long as 75 years ago showed everyone had at least some immunity to the deadly virus, a team at Oregon Health and Science University (OHSU) found.

The finding may offer comfort to those older than 30, who assumed their immunity was long gone.

The United States stopped routine vaccination against smallpox in 1972, and the World Health Organization announced the disease was eradicated in 1980.

Ninety percent of Americans older than 30 have been vaccinated against smallpox at least once, which means as many as 150 million people have at least some immunity to the virus, said OHSU microbiologist and immunologist Mark Slifka.

In designing a smallpox plan, officials have assumed that no one has much immunity after about 5 years.

Slifka, Erika Hammarlund, and others at OHSU are among the teams testing this premise by looking at the blood of 306 people vaccinated in the past.

Everyone who had ever been vaccinated against smallpox had some degree of immunity, Slifka told a meeting of the American Society for Microbiology.

The people came from 40 different states and 34 countries. "There isn\'t any difference, whether you are vaccinated in Oregon or Florida or France," Hammarlund told a news conference.

"We specifically recruited people who were vaccinated...several times," Slifka said. "It had very little effect." While there is a "burst" of immunity right after getting a vaccination, a person\'s overall immunity seems to return to a set point even after multiple immunizations.

People with some immunity can still become ill, even if they are less likely to die of smallpox, and can pass the disease to others.

Hammarlund said at least half of those tested had high levels of antibodies that, in past studies done when smallpox was still around, protected them from serious infection.

***Editor\'s comment***. These data are supported by old observations that some protection against death due to smallpox lasted for many years after vaccination. However, it is important to note that, although there is protection from death, the protection against developing smallpox diminishes with time, and such infected individuals are capable of infecting others and spreading disease in an outbreak.

Prevalence Of Hiv-Related Diarrhea Remains High in Post-Haart Era {#sec5}
=================================================================

19 May (Reuters Health \[Martha Kerr\])--- Before the advent of highly active antiretroviral therapy (HAART) for HIV infection, the prevalence of diseaseassociated diarrhea was about 50%. The problem still persists in nearly 40% of patients, according to a study from investigators at New York University.

At Digestive Disease Week 2003, the 104th annual meeting of the American Gastroenterological Association, Dr. Uzma Siddiqui presented her center\'s findings from a study of 116 HIV-infected patients and 134 controls attending a primary care clinic. The subjects were asked about their bowel status, general health, and quality of life. "We excluded patients attending GI clinics to reduce bias," she told Reuters Health.

The investigators found that 38.3% of HIV-infected patients reported having diarrhea in the past month, compared with 19.4% of controls. In addition, 26.1% of HIV-positive patients reported having 3 or more bowel movements a day within the past month, compared with 5.2% of controls, with similar numbers in each group reporting 3 or more bowel movement per day within the past 6 months (P ! .001 for all).

When asked how they described their stools, 19.1% of HIV patients described them as "loose" or "liquid," compared with 7.4% of controls. Over-the-counter antidiarrheal medication was taken by 14.8% of HIV-infected patients, compared with 0.7% of controls.

HIV-associated diarrhea is not as frequently reported as it was before the advent of HAART, Dr. Siddiqui told Reuters Health. "Patients are not being hospitalized as often and they are managing their condition themselves, so it is not being brought up and nobody is looking for it. And when we look back in these patients\' charts, there is no mention of it. But diarrhea continues to be a major problem for these patients."
